Cargando…

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

BACKGROUND: Toxicity from chemotherapy is highly variable, unpredictable and results in substantial morbidity and increased healthcare costs. New predictors of toxicity are required to improve the safety and efficacy of chemotherapy. Inflammatory or B symptoms in lymphoma are associated with elevate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Rohini, Cunningham, David, Smith, Paul, Robertson, Graham, Dent, Owen, Clarke, Stephen J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689869/ https://www.ncbi.nlm.nih.gov/pubmed/19450285 http://dx.doi.org/10.1186/1471-2407-9-153

Ejemplares similares

A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma
por: Burton, C, et al.
Publicado: (2006)

Non-Hodgkin Lymphoma (NHL) in Pakistan
por: Pervez, Shahid
Publicado: (2012)

BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL).
por: Butler, M., et al.
Publicado: (1997)

Familial Aggregation of Non-Hodgkin's Lymphoma (NHL). A Case Report
por: Loves, Sandra SCM, et al.
Publicado: (2006)

Assessment of bone marrow infiltration in B-cell non-Hodgkin's lymphoma (NHL).
por: Dorey, E. L., et al.
Publicado: (1989)

NHL - Extranodal T-cell lymphoma
por: Devi, Seema, et al.
Publicado: (2015)

Herbicide use in farming and other jobs in relation to non-Hodgkin’s lymphoma (NHL) risk
por: De Roos, Anneclaire J, et al.
Publicado: (2022)

Survival among AIDS patients with and without non-Hodgkin's lymphoma, and NHL-HIV-negative patients
por: Cornejo-Juárez, Patricia, et al.
Publicado: (2007)

Spatial-temporal analysis of non-Hodgkin lymphoma in the NCI-SEER NHL case-control study
por: Wheeler, David C, et al.
Publicado: (2011)

Analysis of Environmental Chemical Mixtures and Non-Hodgkin Lymphoma Risk in the NCI-SEER NHL Study
por: Czarnota, Jenna, et al.
Publicado: (2015)

The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
por: Chu, Yaya, et al.
Publicado: (2022)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects
por: McDuffie, Helen H, et al.
Publicado: (2009)

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
por: Linch, D. C., et al.
Publicado: (1996)

A case report of surgical management of a solitary Non-Hodgkin's Lymphoma (NHL) arising from the proximal sciatic nerve
por: Gobinath, Sivakumaran, et al.
Publicado: (2023)

Favorable outcome in non-Hodgkin lymphoma of the maxillary sinus treated with R-CHOP
por: Doumas, Stergios, et al.
Publicado: (2013)

Kaposi’s sarcoma-associated herpesvirus (KSHV) serum DNA not associated with subsequent non-Hodgkin’s lymphoma (NHL) risk
por: Beachler, Dan, et al.
Publicado: (2010)

Single Nucleotide Polymorphisms in MIR143 Contribute to Protection against Non-Hodgkin Lymphoma (NHL) in Caucasian Populations
por: Bradshaw, Gabrielle, et al.
Publicado: (2019)

Targeting Asparagine and Serine Metabolism in Germinal Centre-Derived B Cells Non-Hodgkin Lymphomas (B-NHL)
por: Eraslan, Zuhal, et al.
Publicado: (2021)

Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2)
por: Yokoyama, Masahiro, et al.
Publicado: (2019)

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice
por: Bascuas, Thais, et al.
Publicado: (2018)

SNP variants associated with non-Hodgkin lymphoma (NHL) correlate with human leukocyte antigen (HLA) class II expression
por: Ten, Lik-Chin, et al.
Publicado: (2017)

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)
por: Yokoyama, Masahiro, et al.
Publicado: (2021)

The outcome of older adults with classic Hodgkin lymphoma in British Columbia
por: Cheng, Phoebe T. M., et al.
Publicado: (2022)

Innate Immunity and Non-Hodgkin’s Lymphoma (NHL) Related Genes in a Nested Case-Control Study for Gastric Cancer Risk
por: Park, Sue K., et al.
Publicado: (2012)

In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin’s lymphoma (NHL)
por: Aya-Bonilla, Carlos, et al.
Publicado: (2014)

Evaluation of Bone Mineral Density in Children with Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL): Chemotherapy with/without Radiotherapy
por: Ghassemi, Ali, et al.
Publicado: (2016)

CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi
por: Gopal, Satish, et al.
Publicado: (2016)

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases.
por: Morton, J. E., et al.
Publicado: (1993)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma
por: Yang, Jing, et al.
Publicado: (2022)

Anti-Spike (S) Antibody Production Post Covid-19 Vaccination after B Cell Depleting Therapy (BCDT) for Non-Hodgkin Lymphoma (NHL)
por: Molina, Josselyn Glamyr
Publicado: (2021)

Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy
por: Kim, Tark, et al.
Publicado: (2012)

High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas
por: Huang, Li-Wen, et al.
Publicado: (2021)

Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting
por: Okello, Clement D., et al.
Publicado: (2020)

Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin’s Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease
por: Huang, Shuang, et al.
Publicado: (2021)

Translation and Pilot Validation of the EORTC QLQ-NHL-HG29 Module in Indian Languages (Hindi and Marathi) for Use in Indian Patients with Non-Hodgkin's Lymphoma
por: Patil, Roshankumar, et al.
Publicado: (2022)

P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY
por: Spurgeon, Stephen, et al.
Publicado: (2023)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q4tplv74i3vof7bhp7che7iqn1